MRI based volumetric measurements of vestibular schwannomas in patients with neurofibromatosis type 2: comparison of three different software tools

被引:0
|
作者
Philipp Kollmann
Victor-Felix Mautner
Johannes Koeppen
Ralph Wenzel
Jan M. Friedman
Johannes Salamon
Said Farschtschi
机构
[1] University Medical Center Hamburg-Eppendorf,Department of Neurology
[2] University Medical Center Hamburg-Eppendorf,Department of Neurosurgery
[3] Radiological Practice Altona,Department of Medical Genetics
[4] University of British Columbia,Department of Diagnostic and Interventional Radiology and Nuclear Medicine
[5] University Medical Center Hamburg-Eppendorf,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Neurofibromatosis type 2 is a neurogenetic disorder with an incidence of about 1:33.000. Hallmarks are bilateral benign vestibular schwannomas, which can lead to deafness or brainstem compression. Volumetric tumor measurements are essential to assess the efficacy of new therapies. We present a statistical and methodical comparison of three volumetric image analysis tools. We performed volumetric measurements on phantoms with predefined volumes (0.1 to 8.0 ml) and tumors seen on 32 head MRI scans from eight NF2 patients with BrainLab, ITK-Snap, or OsiriX. The software was compared with regard to accuracy and reproducibility of the measurements and time required for analysis. The mean volume estimated by all three software programs differed significantly from the true volume of the phantoms, but OsiriX and BrainLab gave estimates that were not significantly different from each other. For the actual tumors, the estimated volumes with all three software tools showed a low coefficient of variability, but the mean volume estimates differed among the tools. OsiriX showed the shortest analysis time. Volumetric assessment of MRI images is associated to an intrinsic risk of miscalculation. For precise volumes it is mandatory to use the same volumetric tools for all measurements.
引用
收藏
相关论文
共 49 条
  • [21] CLINICAL CHARACTERISTICS AND THERAPEUTIC INTERVENTIONS IN A CASE SERIES OF PEDIATRIC PATIENTS WITH VESTIBULAR SCHWANNOMAS AND NEUROFIBROMATOSIS TYPE 2
    Stitzlein, Lea M.
    Sun, Yusha Y.
    Munir, Faryal
    Mccutcheon, Ian E.
    Slopis, John M.
    Zaky, Wafik
    NEURO-ONCOLOGY, 2024, 26
  • [22] Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
    Karajannis, Matthias A.
    Legault, Genevieve
    Hagiwara, Mari
    Ballas, Marc S.
    Brown, Krysten
    Nusbaum, Annette O.
    Hochman, Tsivia
    Goldberg, Judith D.
    Koch, Kevin M.
    Golfinos, John G.
    Roland, J. Thomas
    Allen, Jeffrey C.
    NEURO-ONCOLOGY, 2012, 14 (09) : 1163 - 1170
  • [23] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
    Peyre, Matthieu
    Goutagny, Stephane
    Bah, Alpha
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2013, 72 (06) : 907 - 913
  • [24] PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
    Garcia, Mekka R.
    Hagiwara, Mari
    Yaffe, Anna
    Mitchell, Carole
    Akshintala, Srivandana
    Nicolaides, Theodore
    Phadnis, Sheetal S.
    Yohay, Kaleb
    Feng, Yang
    Goldberg, Judith D.
    Allen, Jeffrey C.
    Karajannis, Matthias A.
    NEURO-ONCOLOGY, 2024, 26
  • [25] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results COMMENTS
    Schwartz, Marc S.
    Link, Michael J.
    NEUROSURGERY, 2013, 72 (06) : 914 - 914
  • [26] Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
    Webb, M. J.
    Neth, Bryan J.
    Webb, Lauren M.
    Van Gompel, Jamie J.
    Link, Michael J.
    Neff, Brian A.
    Carlson, Matthew L.
    Driscoll, Colin L.
    Dornhoffer, Jim
    Ruff, Michael W.
    Anderson, Kelsey A.
    Kizilbash, Sani H.
    Campian, Jian L.
    Uhm, Joon H.
    Lane, Jack, I
    Benson, John C.
    Blezek, Daniel J.
    Mehta, Parv M.
    Bathla, Girish
    Sener, Ugur T.
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [27] Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients
    Putipun Puataweepong
    Mantana Dhanacha
    Rawee Ruangkanchanasetr
    Keeratikarn Boonyawan
    Ake Hansasuta
    Kriangsak Saetia
    Pornpan Yongvithisatid
    Journal of Neuro-Oncology, 2023, 164 : 587 - 595
  • [28] Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients
    Puataweepong, Putipun
    Dhanacha, Mantana
    Ruangkanchanasetr, Rawee
    Boonyawan, Keeratikarn
    Hansasuta, Ake
    Saetia, Kriangsak
    Yongvithisatid, Pornpan
    JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (03) : 587 - 595
  • [29] Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation
    Fu Zhao
    Bo Wang
    Zhijun Yang
    Qiangyi Zhou
    Peng Li
    Xingchao Wang
    Jing Zhang
    Junting Zhang
    Pinan Liu
    Journal of Neuro-Oncology, 2018, 138 : 417 - 424
  • [30] Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates
    Mathieu, David
    Kondziolka, Douglas
    Flickinger, John C.
    Niranjan, Ajay
    Williamson, Richard
    Martin, Juan J.
    Dade Lunsford, L.
    NEUROSURGERY, 2007, 60 (03) : 460 - 468